{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:55:34Z","timestamp":1791474934894,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11739-026-04384-0","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:29:59Z","timestamp":1778866199000},"page":"1979-1990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists\/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan\u00ae: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Antonella","family":"Berardicurti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-031X","authenticated-orcid":false,"given":"Settimio","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Boccatonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"10319","key":"4384_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL-Lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/S0140-6736(21)01701-3","journal-title":"Lancet"},{"issue":"4","key":"4384_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595","journal-title":"Gut"},{"issue":"5","key":"4384_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"5","key":"4384_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal AJ, Anstee QM, Trauner M et al (2022) Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75(5):1235\u20131246. https:\/\/doi.org\/10.1002\/hep.32204","journal-title":"Hepatology"},{"issue":"5","key":"4384_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","volume":"21","author":"L Puch","year":"2023","unstructured":"Puch L, Payne JY, Zhang L et al (2023) Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol 21(5):1154\u20131168. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.033. (PMID: 35933075; PMCID: PMC9898457)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"4384_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver (2021) EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol 75(3):659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","journal-title":"J Hepatol"},{"issue":"2","key":"4384_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11(2):73. https:\/\/doi.org\/10.3390\/metabo11020073","journal-title":"Metabolites"},{"issue":"10","key":"4384_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184(10):2537\u20132564. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"4384_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n7171. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4384_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan: a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4384_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"4384_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"4384_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT (2020) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Syn Meth. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Syn Meth"},{"key":"4384_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta\u2010analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"4384_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta\u2010analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"4384_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/oxfordjournals.aje.a117644","volume":"142","author":"GA Colditz","year":"1995","unstructured":"Colditz GA, Burdick E, Mosteller F (1995) Heterogeneity in meta\u2010analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 142:371\u2013382","journal-title":"Am J Epidemiol"},{"key":"4384_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046\u20131055","journal-title":"J Clin Epidemiol"},{"key":"4384_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455\u2013463","journal-title":"Biometrics"},{"issue":"11","key":"4384_CR19","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7","journal-title":"Diabetologia"},{"issue":"12","key":"4384_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"8","key":"4384_CR21","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae122","volume":"8","author":"E Korakas","year":"2024","unstructured":"Korakas E, Kountouri A, Pavlidis G et al (2024) Semaglutide concurrently improves vascular and liver indices in patients with type 2 diabetes and fatty liver disease. J Endocr Soc 8(8):bvae122. https:\/\/doi.org\/10.1210\/jendso\/bvae122","journal-title":"J Endocr Soc"},{"issue":"4","key":"4384_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"14","key":"4384_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14141475","volume":"14","author":"E Stratina","year":"2024","unstructured":"Stratina E, Stanciu C, Nastasa R et al (2024) New insights on using oral semaglutide versus dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Diagnostics Basel 14(14):1475. https:\/\/doi.org\/10.3390\/diagnostics14141475","journal-title":"Diagnostics Basel"},{"issue":"4","key":"4384_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"10019","key":"4384_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"11-12","key":"4384_CR26","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","volume":"60","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, Sanyal AJ, Engebretsen KA et al (2024) Semaglutide 2.4\u2009mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther 60(11\u201312):1525\u20131533. https:\/\/doi.org\/10.1111\/apt.18331","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"4384_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMra1610570","volume":"377","author":"EB Tapper","year":"2017","unstructured":"Tapper EB, Lok AS (2017) Use of liver imaging and biopsy in clinical practice. N Engl J Med 377(8):756\u2013768. https:\/\/doi.org\/10.1056\/NEJMra1610570","journal-title":"N Engl J Med"},{"issue":"3","key":"4384_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100284","volume":"3","author":"C Bianco","year":"2021","unstructured":"Bianco C, Casirati E, Malvestiti F, Valenti L (2021) Genetic predisposition similarities between NASH and ASH: identification of new therapeutic targets. JHEP Rep 3(3):100284. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100284","journal-title":"JHEP Rep"},{"issue":"6","key":"4384_CR29","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/hep.28827","volume":"64","author":"A Gastaldelli","year":"2016","unstructured":"Gastaldelli A, Gaggini M, Daniele G et al (2016) Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study. Hepatology 64(6):2028\u20132037. https:\/\/doi.org\/10.1002\/hep.28827","journal-title":"Hepatology"},{"issue":"3","key":"4384_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/dom.13907","volume":"22","author":"A Gastaldelli","year":"2020","unstructured":"Gastaldelli A, Repetto E, Guja C et al (2020) Exenatide and Dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab 22(3):393\u2013403. https:\/\/doi.org\/10.1111\/dom.13907","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"4384_CR31","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"12","key":"4384_CR32","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/dc25-1306","volume":"48","author":"C Caussy","year":"2025","unstructured":"Caussy C, Cusi K, Rosenstock J et al (2025) Relationship between metabolic and histological responses in people with metabolic dysfunction-associated steatohepatitis with and without type 2 diabetes: participant-level exploratory analysis of the SYNERGY-NASH trial with tirzepatide. Diabetes Care 48(12):2074\u20132083. https:\/\/doi.org\/10.2337\/dc25-1306","journal-title":"Diabetes Care"},{"issue":"3","key":"4384_CR33","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/hep.27839","volume":"62","author":"DG Mashek","year":"2015","unstructured":"Mashek DG, Khan SA, Sathyanarayan A, Ploeger JM, Franklin MP (2015) Hepatic lipid droplet biology: getting to the root of fatty liver. Hepatology 62(3):964\u2013967. https:\/\/doi.org\/10.1002\/hep.27839","journal-title":"Hepatology"},{"issue":"4","key":"4384_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.tem.2025.01.002","volume":"36","author":"S Daniels","year":"2025","unstructured":"Daniels S, Karlsson C, Schrauwen P, Parker VER (2025) Glucagon-like peptide-1 receptor agonism and end-organ protection. Trends Endocrinol Metab 36(4):301\u2013315. https:\/\/doi.org\/10.1016\/j.tem.2025.01.002","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"4384_CR35","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2337\/db23-0972","volume":"73","author":"G Della Pepa","year":"2024","unstructured":"Della Pepa G, Patr\u00edcio BG, Carli F et al (2024) GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss. Diabetes 73(10):1605\u20131614. https:\/\/doi.org\/10.2337\/db23-0972","journal-title":"Diabetes"},{"issue":"3","key":"4384_CR36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.25993","volume":"57","author":"J Boursier","year":"2013","unstructured":"Boursier J, Zarski JP, de Ledinghen V et al (2013) Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57(3):1182\u20131191. https:\/\/doi.org\/10.1002\/hep.25993","journal-title":"Hepatology"},{"issue":"3","key":"4384_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-0042-1751081","volume":"42","author":"L Castera","year":"2022","unstructured":"Castera L, Boursier J (2022) Noninvasive algorithms for the case finding of \u201cAt-Risk\u201d patients with NAFLD. Semin Liver Dis 42(3):313\u2013326. https:\/\/doi.org\/10.1055\/s-0042-1751081","journal-title":"Semin Liver Dis"},{"issue":"11","key":"4384_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/diagnostics10110940","volume":"10","author":"S Oeda","year":"2020","unstructured":"Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H (2020) Diagnostic accuracy of FibroScan and factors affecting measurements. Diagnostics 10(11):940. https:\/\/doi.org\/10.3390\/diagnostics10110940","journal-title":"Diagnostics"},{"issue":"32","key":"4384_CR39","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic I, Orli\u0107 L, Franji\u0107 N, Hauser G, \u0160timac D, Mili\u0107 S (2016) Transient elastography (FibroScan\u00ae) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease: where do we stand? World J Gastroenterol 22(32):7236\u20137251. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7236","journal-title":"World J Gastroenterol"},{"key":"4384_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/gastro\/got007","volume":"1","author":"G Wong","year":"2013","unstructured":"Wong G (2013) Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep 1:19\u201326. https:\/\/doi.org\/10.1093\/gastro\/got007","journal-title":"Gastroenterol Rep"},{"key":"4384_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051201","author":"A Ali","year":"2022","unstructured":"Ali A, Juboori A, Petroski G, Diaz-Arias A, Syed-Abdul M, Wheeler A, Ganga R, Pitt J, Spencer N, Hammoud G, Rector R, Parks E, Ibdah J (2022) The utility and diagnostic accuracy of transient elastography in adults with morbid obesity: a prospective study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11051201","journal-title":"J Clin Med"},{"key":"4384_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29489","author":"R Vuppalanchi","year":"2018","unstructured":"Vuppalanchi R, Siddiqui M, Van Natta M, Hallinan E, Brandman D, Kowdley K, Neuschwander Tetri B, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia J, Kleiner D, Sanyal A, Chalasani N (2018) Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. https:\/\/doi.org\/10.1002\/hep.29489","journal-title":"Hepatology"},{"key":"4384_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3748\/wjg.v27.i7.641","volume":"27","author":"L Huang","year":"2021","unstructured":"Huang L, Yu X, Li J, Lin H, Kang N, Jiang J, Zhu Y, Liu Y, Zeng D (2021) Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection. World J Gastroenterol 27:641\u2013653. https:\/\/doi.org\/10.3748\/wjg.v27.i7.641","journal-title":"World J Gastroenterol"},{"key":"4384_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/gut.2005.069153","volume":"55","author":"J Foucher","year":"2005","unstructured":"Foucher J, Chanteloup E, Vergniol J, Cast\u00e9ra L, Bail B, Adhoute X, Bertet J, Couzigou P, Ledinghen V (2005) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:403\u2013408. https:\/\/doi.org\/10.1136\/gut.2005.069153","journal-title":"Gut"},{"issue":"6","key":"4384_CR45","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"P Eddowes","year":"2019","unstructured":"Eddowes P, Sasso M, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha I, Cobbold J, Deeks J, Paradis V, Bedossa P, Newsome P (2019) Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156(6):1717\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042","journal-title":"Gastroenterology"},{"issue":"2","key":"4384_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J, Bail L, Chanteloup E, Haaser M, Darriet M, Couzigou P, De L\u00e9dinghen V (2005) Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343\u2013350. https:\/\/doi.org\/10.1053\/j.gastro.2004.11.018","journal-title":"Gastroenterology"},{"key":"4384_CR47","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v11.i7.340","author":"S Kataria","year":"2023","unstructured":"Kataria S, Juneja D, Singh O (2023) Transient elastography (FibroScan) in critical care: applications and limitations. World J Meta-Anal. https:\/\/doi.org\/10.13105\/wjma.v11.i7.340","journal-title":"World J Meta-Anal"},{"key":"4384_CR48","doi-asserted-by":"publisher","first-page":"516","DOI":"10.6061\/clinics\/2017(09)01","volume":"72","author":"T Ragazzo","year":"2017","unstructured":"Ragazzo T, Paranagu\u00e1-Vezozzo D, Lima F, De Campos Mazo D, Pessoa M, Oliveira C, Alves V, Carrilho F (2017) Accuracy of transient elastography-FibroScan\u00ae, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics 72:516\u2013525. https:\/\/doi.org\/10.6061\/clinics\/2017(09)01","journal-title":"Clinics"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04384-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:33:28Z","timestamp":1789540408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04384-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4384"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04384-0","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}